Patents by Inventor Robert J. Lutz

Robert J. Lutz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240368270
    Abstract: Methods of administering immunoconjugates that bind to FOLR1 are provided. The methods comprise administering an anti-FOLR1 immunoconjugate to a person in need thereof, for example, a cancer patient, at a therapeutically effective dosing regimen that results in minimal adverse effects.
    Type: Application
    Filed: April 12, 2024
    Publication date: November 7, 2024
    Inventors: Robert J. LUTZ, Jose PONTE
  • Publication number: 20210155688
    Abstract: Methods of administering immunoconjugates that bind to FOLR1 are provided. The methods comprise administering an anti-FOLR1 immunoconjugate to a person in need thereof, for example, a cancer patient, at a therapeutically effective dosing regimen that results in minimal adverse effects.
    Type: Application
    Filed: January 15, 2021
    Publication date: May 27, 2021
    Inventors: Robert J. LUTZ, Jose PONTE
  • Publication number: 20180362646
    Abstract: The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved versions of these antibodies, immunoconjugates and compositions comprising these antibodies, and the uses of same in diagnostic, research and therapeutic applications. The invention also relates to a polynucleotide encoding these antibodies, vectors comprising the polynucleotides, host cells transformed with polynucleotides and methods of producing these antibodies.
    Type: Application
    Filed: May 14, 2018
    Publication date: December 20, 2018
    Inventors: Mary G. Hoffee, Daniel Tavares, Robert J. Lutz
  • Patent number: 10000566
    Abstract: The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved versions of these antibodies, immunoconjugates and compositions comprising these antibodies, and the uses of same in diagnostic, research and therapeutic applications. The invention also relates to a polynucleotide encoding these antibodies, vectors comprising the polynucleotides, host cells transformed with polynucleotides and methods of producing these antibodies.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: June 19, 2018
    Assignee: IMMUNOGEN, INC.
    Inventors: Mary G. Hoffee, Daniel Tavares, Robert J. Lutz
  • Publication number: 20170080102
    Abstract: The invention features methods for characterizing and treating acute myeloid leukemia (AML) (e.g., newly diagnosed, relapsed, and refractory AML) in a subject using immunoconjugates of the invention. In one aspect, the invention generally features a method of treating acute myeloid leukemia in a subject (e.g., a human), the method involving administering an effective amount of an immunoconjugate to a pre-selected subject, where the immunoconjugate contains a humanized or chimeric antibody or fragment conjugated to a cytotoxic benzodiazepine dimer compound via a cleavable disulfide linker.
    Type: Application
    Filed: May 19, 2015
    Publication date: March 23, 2017
    Inventors: Kathleen R. Whiteman, Paul Noordhuis, Yelena Kovtun, Robert J. Lutz, Gerrit Jan Schuurhuis, Russell Marlin Walker
  • Publication number: 20160362490
    Abstract: The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved versions of these antibodies, immunoconjugates and compositions comprising these antibodies, and the uses of same in diagnostic, research and therapeutic applications. The invention also relates to a polynucleotide encoding these antibodies, vectors comprising the polynucleotides, host cells transformed with polynucleotides and methods of producing these antibodies.
    Type: Application
    Filed: May 13, 2016
    Publication date: December 15, 2016
    Applicant: IMMUNOGEN INC.
    Inventors: Mary G. HOFFEE, Daniel TAVARES, Robert J. LUTZ
  • Patent number: 9359442
    Abstract: The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved versions of these antibodies, immunoconjugates and compositions comprising these antibodies, and the uses of same in diagnostic, research and therapeutic applications. The invention also relates to a polynucleotide encoding these antibodies, vectors comprising the polynucleotides, host cells transformed with polynucleotides and methods of producing these antibodies.
    Type: Grant
    Filed: April 10, 2014
    Date of Patent: June 7, 2016
    Assignee: IMMUNOGEN INC.
    Inventors: Mary G. Hoffee, Daniel Tavares, Robert J. Lutz
  • Publication number: 20150343077
    Abstract: Methods of administering immunoconjugates that bind to CD37 are provided. The methods comprise administering an anti-CD37 immunoconjugate to a person in need thereof, for example, a cancer patient, at a therapeutically effective dosing regimen that results in minimal adverse effects.
    Type: Application
    Filed: May 12, 2015
    Publication date: December 3, 2015
    Inventors: Jutta DECKERT, Robert J. LUTZ, Joanne Elizabeth Sarah SCHINDLER, Rodrigo Ricardo RUIZ SOTO
  • Publication number: 20150297744
    Abstract: Methods of administering immunoconjugates that bind to FOLR1 are provided. The methods comprise administering an anti-FOLR1 immunoconjugate to a person in need thereof, for example, a cancer patient, at a therapeutically effective dosing regimen that results in minimal adverse effects.
    Type: Application
    Filed: March 27, 2015
    Publication date: October 22, 2015
    Applicant: ImmunoGen, Inc.
    Inventors: Robert J. LUTZ, Jose Ponte, Yinghui Zhou
  • Publication number: 20150132323
    Abstract: Methods of administering immunoconjugates that bind to FOLR1 are provided. The methods comprise administering an anti-FOLR1 immunoconjugate to a person in need thereof, for example, a cancer patient, at a therapeutically effective dosing regimen that results in minimal adverse effects.
    Type: Application
    Filed: October 8, 2014
    Publication date: May 14, 2015
    Inventors: ROBERT J. LUTZ, JOSE PONTE
  • Publication number: 20140248267
    Abstract: The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved versions of these antibodies, immunoconjugates and compositions comprising these antibodies, and the uses of same in diagnostic, research and therapeutic applications. The invention also relates to a polynucleotide encoding these antibodies, vectors comprising the polynucleotides, host cells transformed with polynucleotides and methods of producing these antibodies.
    Type: Application
    Filed: April 10, 2014
    Publication date: September 4, 2014
    Applicant: IMMUNOGEN INC.
    Inventors: Mary G. HOFFEE, Daniel TAVARES, Robert J. LUTZ
  • Patent number: 8747851
    Abstract: The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved versions of these antibodies, immunoconjugates and compositions comprising these antibodies, and the uses of same in diagnostic, research and therapeutic applications. The invention also relates to a polynucleotide encoding these antibodies, vectors comprising the polynucleotides, host cells transformed with polynucleotides and methods of producing these antibodies.
    Type: Grant
    Filed: November 19, 2012
    Date of Patent: June 10, 2014
    Assignee: Immunogen Inc.
    Inventors: Mary G. Hoffee, Daniel Tavares, Robert J. Lutz
  • Publication number: 20140093523
    Abstract: The invention relates to conjugates of anti-integrin specific antibodies with cytotoxic compounds, the synthesis, selection, and use of such conjugates for use in cancer therapy or other diseases mediated by cell proliferation, cell migration, or inflammation and which pathology involves angiogenesis or neovascularization of new tissue. In addition the invention relates to combination therapy of such diseases wherein the treatment comprises use of said conjugates in combination with one or more other treatment modalities including but not limited to: chemotherapy, surgery or radiation therapy. The preferred conjugates contain maytansinoid compounds linked to the antibody by a disulfide linkage, and preferred chemotherapeutic agents are doxorubicin, a taxane, a camptothecin, a podophyllotoxin, a nucleoside analog, or a pyrimidine analog.
    Type: Application
    Filed: December 4, 2013
    Publication date: April 3, 2014
    Applicants: Immunogen, Inc., Janssen Biotech, Inc.
    Inventors: Qiming Chen, Mohit Trikha, Robert J. Lutz, Rita M. Steeves, Godfrey Amphlett
  • Patent number: 8603483
    Abstract: The invention relates to conjugates of anti-integrin specific antibodies with cytotoxic compounds, the synthesis, selection, and use of such conjugates for use in cancer therapy or other diseases mediated by cell proliferation, cell migration, or inflammation and which pathology involves angiogenesis or neovascularization of new tissue. In addition the invention relates to combination therapy of such diseases wherein the treatment comprises use of said conjugates in combination with one or more other treatment modalities including but not limited to: chemotherapy, surgery or radiation therapy. The preferred conjugates contain maytansinoid compounds linked to the antibody by a disulfide linkage, and preferred chemotherapeutic agents are doxorubicin, a taxane, a camptothecin, a podophyllotoxin, a nucleoside analog, or a pyrimidine analog.
    Type: Grant
    Filed: November 30, 2005
    Date of Patent: December 10, 2013
    Assignees: Janssen Biotech, Inc., Immunogen, Inc.
    Inventors: Qiming Chen, Mohit Trikha, Robert J. Lutz, Rita M. Steeves, Godfrey Amphlett
  • Patent number: 8563700
    Abstract: The present invention encompasses a combination of at least one conjugate and one or more chemotherapeutic agent(s) which when administered exerts an unexpectedly enhanced therapeutic effect. The therapeutic effectiveness of the combination is greater than that of the conjugate alone or the administration of one or more of the drug(s) without the conjugate. The present invention is also directed to compositions comprising at least one conjugate and at one or more of chemotherapeutic agent and to methods of treating cancer using at least one conjugate and at least one or more of chemotherapeutic agent(s). The present invention also provides methods of modulating the growth of selected cell populations, such as cancer cells, by administering a therapeutically effective amount of one or more chemotherapeutic agent(s) and at least one conjugate. In each case, such combination has therapeutic synergy or improves the therapeutic index in the treatment of cancer over the anticancer agent(s) alone.
    Type: Grant
    Filed: June 16, 2009
    Date of Patent: October 22, 2013
    Assignee: ImmunoGen, Inc.
    Inventors: Robert J. Lutz, Kathleen R. Whiteman
  • Patent number: 8409166
    Abstract: Methods and devices are disclosed for selective delivery of therapeutic substances to specific histologic or microanatomic areas of organs. Introduction of the therapeutic substance into a hollow organ space (such as an hepatobiliary duct or the gallbladder lumen) at a controlled pressure, volume or rate allows the substance to reach a predetermined cellular layer (such as the ephithelium or sub-epithelial space). The volume or flow rate of the substance can be controlled so that the intralumenal pressure reaches a predetermined threshold level beyond which subsequent subepithelial delivery of the substance occurs. Alternatively, a lower pressure is selected that does not exceed the threshold level, so that delivery occurs substantially only to the epithelial layer. Such site specific delivery of therapeutic agents permits localized delivery of substances (for example to the interstitial tissue of an organ) in concentrations that may otherwise produce systemic toxicity.
    Type: Grant
    Filed: April 26, 2011
    Date of Patent: April 2, 2013
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Stephen M. Wiener, Robert F. Hoyt, Jr., John R. Deleonardis, Randall R. Clevenger, Robert J. Lutz, Douglas V. Christini, Brian Safer
  • Patent number: 8388960
    Abstract: Methods of killing or inhibiting tumors comprising of heterogeneous or mixed cell populations is described. The killing or inhibition of tumors is achieved by selectively targeting a unique ligand suspected of being expressed on a particular cell population to also kill a cell population lacking the unique ligand. These conjugates have therapeutic use as they are delivered to a specific cell population to kill these cells and the cytotoxic drug is released to kill non-targeted cells, thereby eliminating the tumor.
    Type: Grant
    Filed: September 9, 2011
    Date of Patent: March 5, 2013
    Assignee: Immunogen Inc.
    Inventors: Viktor S. Goldmakher, Robert J. Lutz, Ravi V. J. Chari, Yelena V. Kovtun, John M. Lambert, Rita Steeves, Hans K. Erickson, Wayne C. Widdison
  • Patent number: 8337855
    Abstract: The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved versions of these antibodies, immunoconjugates and compositions comprising these antibodies, and the uses of same in diagnostic, research and therapeutic applications. The invention also relates to a polynucleotide encoding these antibodies, vectors comprising the polynucleotides, host cells transformed with polynucleotides and methods of producing these antibodies.
    Type: Grant
    Filed: February 2, 2011
    Date of Patent: December 25, 2012
    Assignee: Immunogen Inc.
    Inventors: Mary G. Hoffee, Daniel Tavares, Robert J. Lutz
  • Publication number: 20120282282
    Abstract: The invention relates to charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of using the same to reduce ocular toxicity associated with administration of antibody drug conjugates.
    Type: Application
    Filed: April 4, 2012
    Publication date: November 8, 2012
    Applicant: ImmunoGen, Inc.
    Inventors: Robert J. Lutz, Ravi V.J. Chari
  • Patent number: 8137669
    Abstract: Methods of killing or inhibiting tumors comprising of heterogeneous or mixed cell populations is described. The killing or inhibition of tumors is achieved by selectively targeting a unique ligand suspected of being expressed on a particular cell population to also kill a cell population lacking the unique ligand. These conjugates have therapeutic use as they are delivered to a specific cell population to kill these cells and the cytotoxic drug is released to kill non-targeted cells, thereby eliminating the tumor.
    Type: Grant
    Filed: August 5, 2008
    Date of Patent: March 20, 2012
    Assignee: Immunogen, Inc.
    Inventors: Viktor S. Goldmakher, Robert J. Lutz, Ravi V. J. Chari, Yelena V. Kovtun, John M. Lambert, Rita Steeves, Hans K. Erickson